Skip to content

other alternative medical treatment option of abnormal uterine bleeding

Comparison of efficacy of levonorgestrel intrauterine sytem (LNG-IUS) versus norethisterone acetate (NETA) in medical management of abnormal uterine bleeding (AUB) a non randomized intervention trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025469
Enrollment
130
Registered
2020-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: LNG-IUS: LNG IUS is a hormonal intrauterine device classified as a long-acting reversible contraceptive method. T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone

Sponsors

AIIMS rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women having AUB of age group 35-50 years attending Gynaecology OPD With uterine size less than or equal to 12 weeks with no cervical, vaginal pathologies and negative pap smear. • Histopathological report negative for malignancy. in case of LNG-IUS group who require contraception

Exclusion criteria

Exclusion criteria: Women with congenital anomalies or acquired uterine anomaly, intramural and subserous fibroid >3 cm and submucous fibroids distorting uterine cavity, acute pelvic inflammatory disease, genital bleeding of unknown aetiology, liver disease, and known or suspected carcinoma of breast. 2) Women not giving consent 3) Women wishing for surgical management. 4) Women diagnosed with endometrial cancer. 5) Women EH with atypia, age >50 years, other pathology e.g., submucosal myomas or polyps, adnexal abnormality, genital infection, hormone therapy or any medication which might affect the menstrual blood loss , steroid hormones or anticoagulants, previous endometrial ablation, diabetic and/or hypertensive patients and 6) The patients who have thromboembolism, pregnancy, submucosal myoma having component inside the cavity over 50% and myomas bigger then 5 cm are excluded. 7) Not willing for medical management 8)tubectomised (bilateral tubal ligated)

Design outcomes

Primary

MeasureTime frame
outcome will be studied after follow up of 3 and 6 monthsTimepoint: outcome will be studied after follow up of 3 and 6 months

Secondary

MeasureTime frame
will be studied after 3 and 6 months followTimepoint: will be studied after 3 and 6 months

Countries

India

Contacts

Public ContactReena Kumari

OBG department OPD AIIMS rishikesh

jaya_sunil@yahoo.com9997310120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026